NDAORALTABLET
Approved
May 2011
Lifecycle
LOE Approaching
Competitive Pressure
35/100
Clinical Trials
1
Data completeness
4/8 — Partial
Drug data last refreshed 20h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
EDURANT (rilpivirine hydrochloride) is an oral small-molecule non-nucleoside reverse transcriptase inhibitor (NNRTI) approved by the FDA on May 20, 2011, for the treatment of HIV-1 infection. It is administered as a tablet and represents a key antiretroviral therapy option in combination regimens for treatment-naive and treatment-experienced patients. EDURANT offers a favorable tolerability profile compared to some older NNRTIs, positioning it as an important component of modern HIV treatment strategies.
$0.0BPart D
10mo to LOEMechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
A Study on the Safety and Effectiveness of Rilpivirine Hydrochloride (Edurant) Among Adult Filipino Patients With Human Immunodeficiency Virus Type-I Infection
Started Jun 2013
0Human Immunodeficiency Virus Type 1 (HIV-1) Infection
Why This Matters for Your Career
Worked on EDURANT at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.